Abstract:Purpose: Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, with high mortality and a lack of targeted therapies. To identify and prioritize druggable targets, we performed genome analysis together with genome-scale siRNA and oncology drug profiling using low-passage tumor cells derived from a patient with treatment-resistant HPV-negative HNSCC.Experimental Design: A tumor cell culture was established and subjected to whole-exome sequencing, RNA sequencing, comparative genome hybridization, and high-throughput phenotyping with a siRNA library covering the druggable genome and an oncology drug library. Secondary screens of candidate target genes were performed on the primary tumor cells and two nontumorigenic keratinocyte cell cultures for validation and to assess cancer specificity. siRNA screens of the kinome on two isogenic pairs of p53-mutated HNSCC cell lines were used to determine generalizability. Clinical utility was addressed by performing drug screens on two additional HNSCC cell cultures derived from patients enrolled in a clinical trial.Results: Many of the identified copy number aberrations and somatic mutations in the primary tumor were typical of HPV(-) HNSCC, but none pointed to obvious therapeutic choices. In contrast, siRNA profiling identified 391 candidate target genes, 35 of which were preferentially lethal to cancer cells, most of which were not genomically altered. Chemotherapies and targeted agents with strong tumor-specific activities corroborated the siRNA profiling results and included drugs that targeted the mitotic spindle, the proteasome, and G2-M kinases WEE1 and CHK1 We also show the feasibility of ex vivo drug profiling for patients enrolled in a clinical trial.Conclusions: High-throughput phenotyping with siRNA and drug libraries using patient-derived tumor cells prioritizes mutated driver genes and identifies novel drug targets not revealed by genomic profiling. Functional profiling is a promising adjunct to DNA sequencing for precision oncology. Clin Cancer Res; 24(12); 2828-43. ©2018 AACR.

Toward the Use of Precision Medicine for the Treatment of Head and Neck Squamous Cell Carcinoma.

Advances in Nonsurgical Treatment of Head and Neck Squamous Cell Carcinoma

Biomarkers Of Head And Neck Cancer Stem Cells And Targeted Therapeutic Strategies

New Advances in the Therapeutic Strategy of Head and Neck Squamous Cell Carcinoma: A Review of Latest Therapies and Cutting-Edge Research

Pharmacogenomic landscape of head and neck squamous cell carcinoma informs precision oncology therapy

Targeted therapies for non-HPV-related head and neck cancer: challenges and opportunities in the context of predictive, preventive, and personalized medicine

Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma

Future Perspectives of Precision Medicine for NSCLC

Developments and future prospects of personalized medicine in head and neck squamous cell carcinoma diagnoses and treatments

The Use of Immune Regulation in Treating Head and Neck Squamous Cell Carcinoma (HNSCC)

Revolutionizing head and neck squamous cell carcinoma treatment with nanomedicine in the era of immunotherapy

Exploring the frontiers: tumor immune microenvironment and immunotherapy in head and neck squamous cell carcinoma

Targeted Molecular Imaging of Head and Neck Squamous Cell Carcinoma: a Window into Precision Medicine

Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer

Progress in Precision Medicine for Head and Neck Cancer

Immunotherapeutic Strategies for Head and Neck Squamous Cell Carcinoma (HNSCC): Current Perspectives and Future Prospects

Advances in tumor immune microenvironment of head and neck squamous cell carcinoma: A review of literature

Targeted therapy for head and neck cancer: signaling pathways and clinical studies

The Role of the PI3K/Akt/mTOR Axis in Head and Neck Squamous Cell Carcinoma

Hypoxia-derived molecular subtype and gene signature characterize prognoses and therapeutic responses in head and neck squamous cell carcinoma

Recent Clinical and Preclinical Advances in External Stimuli-Responsive Therapies for Head and Neck Squamous Cell Carcinoma